Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sun, Kai, Welniak, Lisbeth A., Panoskaltsis-Mortari, Angela, O'Shaughnessy, Matthew J., Liu, Haiyan, Barao, Isabel, Riordan, William, Sitcheran, Raquel, Wysocki, Christian, Serody, Jonathan S., Blazar, Bruce R., Sayers, Thomas J., Murphy, William J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2004
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC419567/
https://ncbi.nlm.nih.gov/pubmed/15148407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0401563101
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller